OTC · PPCBD
Propanc Biopharma, Inc.
Healthcare · Biotechnology
$5.68
Up+$0.68 (+13.60%)
Updated Sep 23, 2026, 9:48 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 87.31K
- P/E ratio
- -0.15
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 139
- Avg. volume
- 532
Price performance
PPCBD price history
1M range · 0 trading sessions · Daily adjusted prices
PPCBD does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest PPCBD news
The latest Smart Investors Daily articles mentioning PPCBD.
Stock researchCompany · Overview
PPCBD research
Overview
Company profile and research snapshot.
Company profile
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
